The squamous non-small cell lung cancer market is projected to grow at a CAGR of 10.8% till 2030

Advances in molecular biology and tumor immunology have enabled the development of NSCLC targeting therapies, which have the ability to impede cancer growth by altering chemical reactions associated with oncogenic driver mutations

Roots Analysis has announced the addition of “Squamous Non-small Cell Lung Cancer Market, 2021-2031” report to its list of offerings.

Success of approved squamous non-small cell lung cancer therapies, such as Keytruda®, Opdivo® and Portrazza®, has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of these therapies to effectively treat NSCLC, an aggressive form of lung carcinoma, justifies its potential as a promising disease management recourse. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.

To order this 122+ page report, which features 81+ figures, please visit

Leave a Reply